Anti-Mullerian hormone and polycystic ovary syndrome: assessment of the clinical pregnancy rates in in vitro fertilization patients

被引:16
|
作者
Sahmay, Sezai [1 ,2 ]
Guralp, Onur [3 ]
Aydogan, Begum [4 ]
Cepni, Ismail [1 ,2 ]
Oral, Engin [1 ,2 ]
Irez, Tulay [5 ]
机构
[1] Istanbul Univ, Cerrahpasa Med Sch, Dept Obstet & Gynecol, Div Reprod Endocrinol, TR-34300 Istanbul, Turkey
[2] Istanbul Univ, IVF Unit, TR-34300 Istanbul, Turkey
[3] Bozova Publ Hosp, Dept Obstet & Gynecol, Sanliurfa, Turkey
[4] Istanbul Univ, Cerrahpasa Med Sch, Dept Obstet & Gynecol, TR-34300 Istanbul, Turkey
[5] Yeni Yuzyil Univ, Dept Embryol, Istanbul, Turkey
关键词
Anti-Mullerian hormone; antral follicle count; clinical pregnancy rate; follicle stimulating hormone; polycystic ovary syndrome; FOLLICLE-STIMULATING-HORMONE; ANTIMULLERIAN-HORMONE; LIVE-BIRTH; AMH LEVELS; PREDICTION; CYCLES; LEVEL; WOMEN; BASAL; IVF;
D O I
10.3109/09513590.2013.769519
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Objective: The purpose of this study is to investigate the role of serum anti-Mullerian hormone (AMH), follicle-stimulating hormone (FSH) and antral follicle count (AFC) for the prediction of clinical pregnancy rates (CPR) in women with polycystic ovary syndrome (PCOS) undergoing IVF treatment. Design: Prospective cohort study. Setting: University hospital. Patients: One hundred and fifty consecutive women with PCOS. Interventions: All women underwent controlled ovarian stimulation with long agonist protocol followed by IVF procedure. Outcomes of pregnant and non-pregnant groups were compared. Main outcome measure: CPR; AMH, FSH and AFC means and percentiles. Results: Fifty-one (34%) clinical pregnancies were observed in 150 women. Mean AMH was 6.7 +/- 2.8 and 7.1 +/- 4.3 ng/mL in pregnant and non-pregnant women, respectively (p = 0.594). The CPR were 27.8%, 35.0% and 37.8% in <25%, 25%-75% and >75% AMH percentiles, respectively (p = 0.656). There were also no significant difference in mean FSH and AFC between pregnant and non-pregnant women (p = 0.484 and p = 0.165, respectively). Conclusion: AMH, FSH and AFC are not predictive for CPR in women with PCOS undergoing IVF treatment. Mean AMH values were not significantly different between pregnant and non-pregnant women. Although CRP increased in parallel with the raise in AMH percentiles, this remained insignificant.
引用
收藏
页码:440 / 443
页数:4
相关论文
共 50 条
  • [41] Anogenital distance and anti-Mullerian hormone combined improves the diagnosis of polycystic ovary syndrome
    Prieto-Sanchez, Maria T.
    Hernandez-Penalver, Ana, I
    Sanchez-Ferrer, Maria L.
    Mendiola, Jaime
    Torres-Cantero, Alberto M.
    HUMAN FERTILITY, 2022, 25 (02) : 274 - 282
  • [42] Utility of Serum Anti-Mullerian Hormone Measurement as Part of Polycystic Ovary Syndrome Diagnosis
    Piltonen, Terhi T.
    Viita-aho, Johanna
    Saarela, Ulla
    Melin, Johanna
    Forslund, Maria
    SEMINARS IN REPRODUCTIVE MEDICINE, 2024, 42 (01) : 49 - 59
  • [43] Circulating Anti-Mullerian Hormone Levels in Daughters of Women with and without Polycystic Ovary Syndrome
    Olszanecka-Glinianowicz, Magdalena
    Zachurzok, Agnieszka
    Drosdzol-Cop, Agnieszka
    Bozetowicz-Wikarek, Maria
    Owczarek, Aleksander
    Gawlik, Aneta
    Chudek, Jerzy
    Skrzypulec-Plinta, Violetta
    Malecka-Tendera, Ewa
    HORMONE RESEARCH IN PAEDIATRICS, 2016, 85 (06): : 372 - 378
  • [44] Clinical significance of serum concentration of anti-Mullerian hormone in obese women with polycystic ovary syndrome
    El-Halawaty, Samir
    Rizk, Ahmed
    Kamal, Manal
    AboulHassan, Mona
    Al-Sawah, Heba
    Noah, Olfat
    Al-Inany, Hesham
    REPRODUCTIVE BIOMEDICINE ONLINE, 2007, 15 (05) : 495 - 499
  • [45] Effect of electroacupuncture on anti-Mullerian hormone expression in rats with polycystic ovarian syndrome
    Zhou Jing
    Sun Yi
    Sun Jie
    Zhao Ji-meng
    Cui Yun-hua
    Wu Ling-xiang
    Wu Huan-gan
    Shi Yin
    Li Liang
    JOURNAL OF ACUPUNCTURE AND TUINA SCIENCE, 2019, 17 (02) : 80 - 88
  • [46] Elevated Anti-Mullerian Hormone Is an Independent Risk Factor for Preterm Birth Among Patients With Overweight Polycystic Ovary Syndrome
    Du, Mingze
    Zhang, Junwei
    Yu, Xiaona
    Guan, Yichun
    FRONTIERS IN ENDOCRINOLOGY, 2021, 12
  • [47] Trends in anti-Mullerian hormone concentrations across different stages of pregnancy in women with polycystic ovary syndrome
    Koeninger, Angela
    Kampmeier, Antje
    Schmidt, Boerge
    Frank, Mirjam
    Strowitzki, Thomas
    Kimmig, Rainer
    Gellhaus, Alexandra
    Mach, Pawel
    REPRODUCTIVE BIOMEDICINE ONLINE, 2018, 37 (03) : 367 - 374
  • [48] Anti-Mullerian hormone and antral follicle count for prediction of ovarian stimulation response in polycystic ovary syndrome
    El-Mazny, Akmal
    Abou-Salem, Nermeen
    GYNECOLOGICAL ENDOCRINOLOGY, 2013, 29 (09) : 826 - 829
  • [49] Anti-Mullerian Hormone and Polycystic Ovary Syndrome in Women and Its Male Equivalent
    di Clemente, Nathalie
    Racine, Chrystele
    Rey, Rodolfo A.
    BIOMEDICINES, 2022, 10 (10)
  • [50] Differences of the association of anti-Mullerian hormone with clinical or biochemical characteristics between women with and without polycystic ovary syndrome
    Woo, Hee-Yeon
    Kim, Kye-Hyun
    Rhee, Eun-Jung
    Park, Hyosoon
    Lee, Mi-Kyung
    ENDOCRINE JOURNAL, 2012, 59 (09) : 781 - 790